Theravance Biopharma, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development and commercialization of small-molecule medicines. The company has built its portfolio around respiratory disease, immunology and other critical care areas, with its lead marketed product, YUPELRI® (revefenacin), approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In addition to its marketed asset, Theravance Biopharma maintains a diverse clinical pipeline targeting conditions such as neurogenic orthostatic hypotension (nOH) and gastrointestinal disorders.
Headquartered in South San Francisco, California, Theravance Biopharma leverages in-house research capabilities alongside strategic partnerships to advance its programs through late-stage clinical trials. The company collaborates with global pharmaceutical partners—most notably Viatris (formerly Mylan) for the commercialization of YUPELRI®—to extend its reach into markets across North America, Europe and Asia. Its internal R&D operations are supported by a team of medicinal chemists, clinical scientists and regulatory experts dedicated to delivering differentiated therapies.
Founded in 2014 following a corporate separation from Theravance, Inc., the company is led by President and Chief Executive Officer Rick E. Winningham, who brings extensive experience in pharmaceuticals and biotechnology. Under his leadership, Theravance Biopharma has advanced multiple programs into pivotal studies while maintaining a focus on small-molecule innovation. The company’s management team and board of directors include industry veterans with backgrounds in drug discovery, development and commercialization.
AI Generated. May Contain Errors.
